Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Yabusaki H, Matsuyama J, Takahashi M, Makiyama A, Hayashi H, Chamoto K, Honjo T, Nakagawa K, Ichikawa W, Fujii M. Kawakami H, et al. Among authors: sato t. Eur J Cancer. 2023 May;184:10-20. doi: 10.1016/j.ejca.2023.02.003. Epub 2023 Feb 10. Eur J Cancer. 2023. PMID: 36889037
A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer.
Sakai Y, Kurose K, Sakaeda K, Abo H, Atarashi Y, Ide N, Sato T, Kanda E, Fukuda M, Oga T, Noda K, Oka M. Sakai Y, et al. Among authors: sato t. Clin Chim Acta. 2021 Aug;519:51-59. doi: 10.1016/j.cca.2021.04.008. Epub 2021 Apr 15. Clin Chim Acta. 2021. PMID: 33865813 Free article.
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.
Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M. Kurose K, et al. Among authors: sato t. Adv Clin Chem. 2023;112:155-204. doi: 10.1016/bs.acc.2022.09.004. Epub 2022 Nov 17. Adv Clin Chem. 2023. PMID: 36642483 Review.
Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).
Ogata Y, Sadahiro S, Sakamoto K, Tsuchiya T, Takahashi T, Ohge H, Sato T, Kondo K, Baba H, Itabashi M, Ikeda M, Hamada M, Maeda K, Masuko H, Takahashi K, Kusano M, Hyodo I, Sakamoto J, Taguri M, Morita S. Ogata Y, et al. Among authors: sato t. Int J Clin Oncol. 2024 Jun 4. doi: 10.1007/s10147-024-02565-5. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38833114
Acyl modifications in bovine, porcine, and equine ghrelins.
Ida T, Tominaga H, Iwamoto E, Kurogi A, Okura A, Shimada K, Kato J, Kuwano A, Ode H, Nagata S, Kitamura K, Yazawa T, Sato-Hashimoto M, Yasuda M, Miyazato M, Shiimura Y, Sato T, Kojima M. Ida T, et al. Among authors: sato t. Front Endocrinol (Lausanne). 2024 May 17;15:1411483. doi: 10.3389/fendo.2024.1411483. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38828411 Free PMC article.
16,749 results
You have reached the last available page of results. Please see the User Guide for more information.